ERA-EDTA BUD2019 banner 900x344 0418-1.jpg
ERA-EDTA BUD2019 banner 900x344 0418-2.jpg
ERA-EDTA BUD2019 banner 900x344 0418-3.jpg

    You are here

    • You are here:
    • Home > Scientific Programme

Scientific Programme




Diseases of emergence

Rafael Yuste, New York, NY, USA







Interface of molecular mechanisms, pathology and genetics of developmental kidney diseases

Sanjay Jain, Saint Louis, MO, USA


Single-cell transcriptomics in kidney disease

Katlin Susztak, Philadelphia, PA, USA


The pre-dialysis to renal replacement therapy transition

Csaba P. Kovesdy, Memphis, TN, USA







Late Breaking Clinical Trials


ERA-EDTA Registry

1. The European EDITH kidney nephrologist survey on treatment modality choice

Vianda Stel, Amsterdam, The Netherlands

2. Trends in excess mortality in patients receiving RRT

Rianne Boenink, Amsterdam, The Netherlands

3. Post-transplant growth patterns in children

Jérome Harambat, Bordeaux, France

4. Dynamic prediction of mortality in advanced CKD using Troponin T – Results from the EQUAL study

Nicholas Chesnaye, Amsterdam, The Netherlands


ASN Highlights

1. AKI

Kathleen D. Liu, San Francisco, CA, USA

2. General nephrology & CKD

Tamara Isakova, Chicago, IL, USA

3. Hypertension

Debbie L. Cohen, Philadelphia, PA, USA


Nephrology pearls (Special closing session)

1. Epidemiology and Clinical Nephrology

Marie Evans, Stockholm, Sweden

2. ESKD and Dialysis

Jonathan Fox, Glasgow, United Kingdom

3. Kidney Transplantation

Bruno Watschinger, Vienna, Austria

4. Glomerulonephritis

Rosanna Coppo, Turin, Italy








Phosphate and FGF23

1. FGF23 signalling in the kidney

Reinhold Erben, Vienna, Austria

2. Regulation of FGF23

Mariano Rodriguez, Cordoba, Spain

3. Phosphate toxicity and the kidney

Carsten A. Wagner, Zurich, Switzerland





Redefining the ontology of kidney diseases using genomic analysis

1. Genetic landscape of hereditary amyloidosis

Luisa Lobato, Porto, Portugal

2. What’s up in hereditary tubulo-interstitial nephritis?

Stanislas Kmoch, Prague, Czech Republic

3. Adult-onset ESRD of unknown aetiology: when should we think genetics?

Nine Knoers, Groningen, The Netherlands


Novel therapies in hereditary kidney diseases

1. New therapeutic targets in Alport syndrome

Roser Torra, Barcelona, Spain

2. Targeted therapies in ADPKD: what will be in the pipeline in 2020?

Ron T. Gansevoort, Groningen, The Netherlands

3. Therapeutic management of cystinuria: today and tomorrow

John Sayer, Newcastle upon Tyne, United Kingdom


Paediatric Nephrology

1. Childhood nephrotic syndrome: lessons from the PODONET registry

Beata S. Lipska-Ziętkiewicz, Gdańsk, Poland

2. Evidence based treatment of minimal change nephrotic syndrome: lessons from the PREDNOS trials

Nicholas Webb, Manchester, United Kingdom

3. Novel therapies for childhood minimal change nephrotic syndrome

Marina Vivarelli, Rome, Italy

4. Blood pressure in children

Kjell Tullus, London, United Kingdom





The many faces of monoclonal gammopathy of undetermined significance

1. MGRS classification: bringing order to the nomenclature chaos

Tri Nguyen, Utrecht, The Netherlands

2. MGRS diagnosis: establishing causality is the hardest job

Jolanta Malyszko, Warsaw, Poland

3. MGRS treatment: should we follow the haematologist or take the lead?

Ben Sprangers, Leuven, Belgium


Molecular mechanisms of kidney atrophy and fibrosis

1. Diabesity-induced CKD: when kidneys get the munchies

Joseph Tam, Jerusalem, Israel

2. Does less fibrosis improve renal function? Insights from collagen I-deficiency

Matthias Mack, Regensburg, Germany

3. Pathology and mechanisms of interstitial granuloma formation

Peter Boor, Aachen, Germany


ANCA-associated vasculitis

1. Extrarenal involvement in AAV and its impact on the outcome of patients

Vladimir Tesar, Prague, Czech Republic

2. ANCA-associated vasculitis in the elderly and very elderly

Maria Weiner, Linköping, Sweden

3. Should the anti-PR3 and anti-MPO patients be treated in a different way?

4. Understanding the role of Rituximab in ANCA associated vasculitis

Federico Alberici, Milan, Italy


Complement mediated kidney injury

1. Histologic classification of lupus nephritis – time for a change?

Ingeborg M. Bajema, Leiden, The Netherlands

2. Pathogenesis of SLE and systemic lupus nephritis – what is new?

Hans-Joachim Anders, Munich, Germany

3. Biologic therapy in lupus nephritis – where are we now?

Gabriella Moroni, Milan, Italy

4. Understanding the pathogenesis of C3 glomerulopathies

Sophie Chauvet, Paris, France


Primary glomerulonephritides

1. THSD7A antibody induced disease - pathophysiology and clinical patterns

Rolf A.K. Stahl, Hamburg, Germany

2. Spontaneous remission in membranous nephropathy – how long should we wait?

Fernando Fervenza, Rochester, MN, USA

3. Serology-based algorithm of the treatment of membranous nephropathy

4. What is the optimal approach to the treatment of IgA nephropathy in 2019?

Jürgen Floege, Aachen, Germany





The many facets of hypoxia in CKD

1. Hypoxia and the progression of polycystic kidney disease

Kai-Uwe Eckardt, Berlin, Germany


2. Sleep disordered breathing: a pervasive problem in CKD

Francesca Mallamaci, Reggio Calabria, Italy

3. Intradialytic hypoxia

Peter Kotanko, New York, NY, USA

4. Chronic interstitial nephritis of unknown etiology is a toxic tubular nephropathy

Marc de Broe, Antwerp, Belgium


Brain and nervous system in CKD

1. The gut-brain axis, b2microglobulin and neuroinflammation: a re-interpretation of an old story?

Michel Jadoul, Brussels, Belgium

2. Anti-inflammatory role of the parasympathetic system in CKD

Annette Bruchfeld, Stockholm, Sweden

3. Cognitive impairment and kidney disease

Giovambattista Capasso, Naples, Italy


The role of diet in the prevention of CKD progression: food for thought

1. Dietary protein restriction: PRO

Denis Fouque, Lyon, France

2. Dietary protein restriction: AGAINST

Marc Vervloet, Amsterdam, The Netherlands

3. Dietary acid and CKD progression

Donald Wesson, Dallas, TX, USA


The gut-kidney-cardiovascular axis

1. Gut microbiota and microbial metabolism in CKD across stages of diseases

Griet Glorieux, Ghent, Belgium

2. Gut dysbiosis and thrombosis

Vipul Chitalia, Boston, USA

3. Gut dysbiosis and vascular calcification

Ziad Massy, Paris, France

4. Role of dietary potassium in natriuresis, blood pressure, and cardio-renal outcomes

Ewout Hoorn, The Netherlands


The paradox of estimated GFR in the era of precision medicine

1. Overview of the error of creatinine and cystatin-c-based formulas in clinical practice

Esteban Porrini, La Laguna, Spain

2. Measured GFR in clinical practice, the Swedish experience

Anders Christensson, Malmö, Sweden

3. Which method to measure GFR and in which clinical conditions?

Pierre Delanaye, Liège, Belgium

4. MRI approaches to asses kidney injury and function

Faikah Güler, Hannover, Germany


New insights in molecular mechanism of cardiovascular diseases in CKD

1. Oxidative stress on myocardial function in CKD

Leticia Prates Roma, Homburg/Saar, Germany

2. Lipoproteins in CKD-associated vascular diseases

Thimoteus Speer, Homburg/Saar, Germany

3. Atherosclerosis, cardiac remodelling and CKD

Heidi Noels, Aachen, Germany

4. Impact of post-translational modification on the genesis and progression of CKD

Joachim Jankowski, Aachen, Germany


Regenerative medicine

1. Drug targeting of endogenous progenitors for kidney regeneration

Paola Romagnani, Florence, Italy

2. From human embryonic nephron stem cells to mature kidney tissue and regeneration

Benjamin Dekel, Ramat Gan, Israel

3. Kidney regeneration using induced pluripotent stem (iPS) cells

Takashi Yokoo, Tokyo, Japan

4. What can organoids teach us about kidney regeneration?

Nuria Montserrat, Barcelona, Spain





Haemodialysis. From incremental approaches to frequent treatments

1. The concept of incremental haemodialysis

Carlo Basile, Acquaviva delle Fonti, Italy

2. Clinical experiences with incremental haemodialysis schedules

Kamyar Kalantar-Zadeh, Orange, CA, USA

3. Assuring adequate preparation and choice for advanced CKD patients facing kidney failure (CKDopps)

Christian Combe, Bordeaux, France


Controversy: does haemodiafiltration improve patient outcomes and survival?

1. No

Francesco Locatelli, Lecco, Italy

2. Yes

Peter J. Blankestijn, Utrecht, The Netherlands

3. Increasing convection: what happens to the different uraemic toxins when increasing convection in post-dilutional HDF?

Angel Argiles Ciscart, Montpellier, France


Start dialysis? Stop dialysis? - Challenging conversations

1. Dialysis or conservative care?

Wim Van Biesen, Ghent, Belgium

2. Is this the time to consider dialysis withdrawal?

Monika Lichodziejewska-Niemierko, Gdańsk, Poland

3. Different conversations for different ethnic groups?

Edwina Brown, London, United Kingdom


Delivering good quality dialysis - what should we measure?

1. Small solute clearance: what are the pitfalls?

Enric Vilar, Stevenage, United Kingdom

2. Patient-reported outcomes: are these fit for purpose?

Ken Farrington, Stevenage, United Kingdom

3. Towards a multidimensional measure of dialysis adequacy?

Pieter Evenepoel, Leuven, Belgium

4. How to measure residual renal function

Andrew Davenport, London, United Kingdom


The hidden risks of haemodialysis

1. Silent ischemia during haemodialysis

Christopher W McIntyre, London, Canada

2. Haemodynamic instability and ischemic brain injury

Adrian Covic, Iași, Romania

3. Tolerability of extracorporeal treatments in 2019

Bernard Canaud, Montpellier, France

4. Clinical Practice Guideline on Vascular Access

Maria Haller, Linz, Austria


CKD-MBD patterns and therapeutic approaches: update 2019

1. Klotho, a new player coming to age

Marc Vervloet, Amsterdam, The Netherlands

2. New insights in pathogenesis and treatment of vascular calcification

Catherine Shanahan, London, United Kingdom

3. Osteoporosis in CKD, a diagnostic and therapeutic challenge on the move

Pieter Evenepoel, Leuven, Belgium

4. Evidence in CKD-MBD guidelines: Is it time to treat? Is it time to wait?

Jordi Bover, Barcelona, Spain





Optimizing peritoneal dialysis prescription

1. Why testing peritoneal membrane characteristics?

Johann Morelle, Brussels, Belgium

2. Optimizing PD initiation and reducing early switches to HD: insights from PDOPPS

Simon Davies, Stoke-on-Trent, United Kingdom

3. Alanyl-glutamine supplementation in peritoneal dialysis fluids

Rebecca Herzog, Vienna, Austria

4. Peritoneal dialysis adequacy and outcomes: what really matters?

Isaac Teitelbaum, Denver, CO, USA


Home haemodialysis: on the move

1. Reducing the costs of end stage renal disease while delivering quality health care: are home therapies the answer?

Wim Van Biesen, Ghent, Belgium

2. Striving to achieve an integrated home dialysis system

Maria Fernanda Slon Robledo, Pamplona, Spain

3. Vascular access in HHD: the Achilles tendon?

Sandip Mitra, Manchester, United Kingdom


Frail elderly: management best at home

1. Integrating geriatric assessment into routine dialysis care

Edwina Brown, London, United Kingdom

2. Addressing potentially inappropriate medications in older adults with kidney disease

Rasheeda Hall, Durham, NC, USA

3. Clinical Practice Guideline on management of older patients with advanced chronic kidney disease

Adrian Covic, Iasi, Romania

4. Outcomes on assisted PD Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis

Angela Yee Moon Wang, Hong Kong, Hong Kong





Overcoming age with frailty evaluation in the kidney transplant recipient

1. Are frailty and sarcopenia definitions precise enough to establish a clinical diagnosis in the patient with chronic disease?

Juan Jesus Carrero, Stockholm, Sweden

2. The best frailty evaluation before kidney transplantation

Daniel Abramowicz, Antwerp, Belgium

3. Outcomes of frail patients after kidney transplantation

Maria José Pérez-Sáez, Barcelona, Spain


Precision medicine for the sensitized transplant recipient

1. Tailoring a transplant route for the sensitized patient on dialysis

Marta Crespo, Barcelona, Spain

2. Taking care: balancing immunosuppression avoiding weapons of mass destruction

Julio Pascual, Barcelona, Spain

3. To transplant or not to transplant: an hamletic dilemma in obese candidates

Davide Bolignano, Reggio Calabria, Italy


Basic immunology and pathology

1. Necroinflammation in kidney transplantation

Andreas Linkermann, Dresden, Germany

2. Polyoma nephropathy

Jan Ulrich Becker, Cologne, Germany

3. Banff update

Carmen Lefaucheur, Paris, France


Improving the organ donor pool

1. Controlled Cardiac Donor Death program in Spain: one vision for the future

Beatriz Dominguez Gil, Madrid, Spain

2. Kidney protection in living donors

Charles Ferro, Birmingham, United Kingdom

3. Compatibility barriers/Increasing the pool of marginal donors

Rainer Oberbauer, Vienna, Austria

4. Identifying organizational barriers to organ donation in hospitals

Axel Rahmel, Kidney TP Foundation, Frankfurt, Germany





Improving outcomes in DKD

1. Renal inflammation: its pathogenetic role in diabetic kidney disease

Sydney Tang, Hong Kong, Hong Kong

2. SGLT2 inhibitors in the prevention of renal fibrosis

Andrea Fekete, Budapest, Hungary

3. Update on SGLT2i in CKD

Christoph Wanner, Würzburg, Germany

4. GLP-1 receptor agonists in DKD: mechanisms and outcomes

Johannes F.E. Mann, Munich, Germany


Salt and disease: a changing scenario / Sodium: where is it? How does it harm? How could we intervene?

1. Salt and hypertension: a bacterial affair

Nicola Wilck, Berlin, Germany

2. Tissue sodium storage in end stage kidney disease

Anke Dahlmann, Erlangen, Germany

3. Renal potassium sensing and control of sodium balance

Johannes Loffing, Zurich, Switzerland


Cardiovascular disease in CKD: risk factors and remedies

1. Why is the risk of stroke so high in CKD and in dialysis patients?

Sydney Tang, Hong Kong, Hong Kong

2. Clinical trials and research priorities in dialysis patients

Csaba P. Kovesdy, Memphis, TN, USA

3. Modifiable risk factors for cardiovascular disease in CKD: a hierarchical approach

Rajiv Agarwal, Indianapolis, IN, USA

4. China Kidney Network (CK-NET): Opportunities for Kidney Disease in the Era of Big Data

Luxia Zhang, Beijing, China


Digging the aetiology of hypertension

1. Thrombotic microangiopathy and malignant hypertension

Jean-Michel Halimi, Tours, France

2. Insights from adverse effects of drugs

Petra Tesarova, Prague, Czech Republic

3. Out-of-office BP monitoring and BP variability in chronic kidney disease: current concepts and future directions

Pantelis Sarafidis, Thessaloniki, Greece

4. Novel techniques for blood pressure lowering

Roland Schmieder, Erlangen, Germany


Blood pressure targets

1. Optimal BP target for renoprotection in CKD patients is <140/90

Mustafa Arici, Ankara, Turkey

2. Optimal BP target for renoprotection in CKD patients is <130/80

Pantelis Sarafidis, Thessaloniki, Greece

3. Managing resistant hypertension

Andrzej J. Wiecek, Katowice, Poland

4. What are the ambulatory blood pressure targets?

Manuel Gorostidi, Oviedo, Spain





AKI: current problems in clinical practice

1. Heart failure and AKI

Stephan von Haehling, Gottingen, Germany

2. Genetic susceptibility and AKI

Michael Heung, Ann Arbor, USA

3. References to urinary tract disease in the Works of Thomas of Wroclaw (1297-1378), the Continuator of Arnaldo de Villanova's Medical Thought

Janusz Ostrowski, Warsaw, Poland


Renal Replacement Therapy in the Intensive Care Unit

1. To fill or not to fill: what is the evidence

2. Modality and dose: where do we stand?

Claudio Ronco, Vicenza, Italy

3. When to start dialysis: the final answer?

Julien Maizel, Amiens, France






Renal and intestinal oxalate transport, inflammation and CKD

Felix Knauf, Berlin, Germany


Autophagy in kidney diseases

Yoshitaka Isaka, Suita, Japan


Interallelic interactions of podocin: genetic, molecular, cellular and clinical aspects

Kálmán Tory, Budapest, Hungary


Personalised diagnosis and CKD prediction in genetic tubular disorders

Francesca Becherucci, Florence, Italy


New therapies in the Henoch-Schönlein syndrome

Roberta Fenoglio, Turin, Italy


Role of complement in the pathogenesis and progression of IgA nephropathy

Rosanna Coppo, Turin, Italy


IgA Nephropathy: Evidences from China


PCSK9 in kidney disease

Thimoteus Speer, Homburg/Saar, Germany



Vincent Brandenburg, Aachen, Germany


The Swedish Health databases; an abundance of possibilities for kidney research

Juan Jesus Carrero, Stockholm, Sweden


When should a nephrologist take over – stage 3b or 4 – current perspective

Goce Spasovski, Skopje, F.Y.R. of Macedonia


Muscle protein turnover and low protein diet in patients with CKD

Giacomo Garibotto, Genoa, Italy


“Doctor: how long may I live in dialysis”?

Jürgen Floege, Aachen, Germany


New approaches to enhance removal, particularly of protein bound solutes

Joachim Jankowski, Aachen, Germany


The global fluid study

Mark Lambie, Stoke-on-Trent, United Kingdom


Self-care improves patient outcomes: what is the evidence?

Martin Wilkie, Sheffield, United Kingdom


Molecular targets in renal transplantation: reality or fiction?

Michael Mengel, Edmonton, Canada


TRANSFORM, the largest trial ever done in transplantation: lessons after 3 years

Julio Pascual, Barcelona, Spain


Vitamin D after kidney transplantation

Markus Ketteler, Coburg, Germany


Vascular calcification and Iron metabolism – are they connected?

József Balla, Debrecen, Hungary


Bariatric surgery: untangling the links between diabetes, hypertension and kidney disease?

Anna Solini, Pisa, Italy


The overdriven glomerulus as a CV risk factor

Francesca Mallamaci, Reggio Calabria, Italy


Diabetic kidney disease in Asia: a growing threat

Yuk Lun Cheng, Hong Kong, Hong Kong


Clinical Practice Guideline on management of patients with diabetes and advanced chronic kidney disease

Maria Jose Soler Romeo, Barcelona, Spain


AKI in hospital: risk factors and strategies for prevention

Samira Bell, Dundee, United Kingdom


Prevention of AKI in oncology

Laura Cosmai, Milan, Italy







Primary and Secondary Glomerulonephritis, vasculitis and auto-immune diseases

1. Focal and segmental glomerulosclerosis (FSGS)

Claudio Ponticelli, Milan, Italy

2. Membranous Nephropathy

Jack Wetzels, Nijmegen, The Netherlands

3. IgA Nephropathy

Rosanna Coppo, Turin, Italy

4. New directions in the treatment of ANCA-associated nephritis

Marten Segelmark, Lund, Sweden

5. Lupus Nephritis

Vladimir Tesar, Prague, Czech Republic




1. Concept and global burden of CKD: current status and beyond

Ron Gansevoort, Groningen, The Netherlands

2. What is the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+)?

Marie Evans, Stockholm, Sweden

2. What's new about acute on chronic kidney disease?

4. Anaemia management in CKD patients: past, present and the future

5. Optimal timing and method for RRT proposed to CKD patients

Raymond Vanholder, Ghent, Belgium



Hypertension, Diabetes and CV Disease in CKD

1. Inflammation in CKD: cures at last?

Danilo Fliser, Homburg/Saar, Germany

2. Progress in the prevention and cure of diabetic nephropathy

Lucia Del Vecchio, Lecco, Italy

3. Prognosis by risk calculators in CKD and in ESRD

Friedo W. Dekker, Leiden, The Netherlands

4. LV dysfunction with preserved Ejection Fraction in CKD: epidemiology, mechanism(s) and therapy

Patrick Rossignol, Vandœuvre-lès-Nancy, France



Bone Mineral disorders in CKD

1. How to prevent fractures in CKD?

Pieter Evenepoel, Leuven, Belgium

2. Are we inducing adynamic bone disease, and is that a problem?

Mathias Haarhaus, Stockholm, Sweden

3. Is FGF23 outdated?

Marc Vervloet, Amsterdam, The Netherlands

4. Don’t forget our old friend Vitamin D, which could include the position of novel formulation of non-active vitamin D



Genetic Diseases and Rare Diseases

1. Genomic studies in monogenic and kidney stone disease

Jan Halbritter, Leipzig, Germany

2. Genomic studies in adult CKD patients

Ali G. Gharavi, New York, NY, USA

3. Recent GWAS of kidney function markers

Anna Koettgen, Freiburg, Germany

4. Polycystic kidney disease: new genes and clinical studies

Olivier Devuyst, Zürich, Switzerland

5. Update on tubular and tubulointerstitial diseases

Detlef Bockenhauer, London, United Kingdom



Basic and Transitional Nephrology

1. Kidney diseases at single cell level

Rafael Kramann, Aachen, Germany

2. The new age of kidney imaging

Nicole Endlich, Greifswald, Germany

3. New models of kidney development and regeneration

4. How we survive acute injury and develop chronic disease: kidney, heart and liver not so different after all

Paola Romagnani, Florence, Italy

5. Optogenetic control of inflammation in acute kidney injury

Mark D. Okusa, Charlottesville, VA, USA




1. Renal Biopsy: pitfalls

2. FSGS on renal biopsy: why an integrated approach to diagnosis is necessary

Laura Barisoni, Durham, NC, USA

3. Atypical post-streptococcal GN and complement

Isabelle Brocheriou, Paris, France

4. Diabetic Nephropathy versus Kidney Diseases in Diabetics

Loreto Gesualdo, Bari, Italy

5. The histopathologic spectrum of obesity-related glomerulopathy

Helen Liapis, Little Rock, AR, USA

6. Update on fibrillary and immunotactoid glomerulopathy

Sándor Turkevi-Nagy, Szeged, Hungary

7. Renal side effects of novel anti-cancer drugs

Joris Roelofs, Amsterdam, The Netherlands

8. Tubulointerstitial infiltrates in glomerular diseases

9. How to diagnose chronic TCMR in kidney transplants: Banff and the evidence

Marion Rabant, Paris, France



Haemodialysis and Vascular Access

Vascular access

1. Prevention and treatment of central venous catheter infections

Laura Labriola, Brussels, Belgium

2. New developments in vascular access, what can we expect for the future? Maturation, thrombosis prevention etc.

Joris Rotmans, Leiden, The Netherlands

3. Recent guidelines on vascular access: ERBP, KDIGO, Eur Soc Vasc Surg,

Evi Nagler, Ghent, Belgium


1. Dialysis care: personalized or universal? (Focus on PROMs, so discuss SONG, ICHOM, etc. and how to implement this in daily care?)

Andrew Davenport, London, United Kingdom

2. HDF in children: what can we learn from paediatric studies

Rukshana Shroff, London, United Kingdom

3. How to increase home and self-care haemodialysis?

Sandip Mitra, Manchester, United Kingdom



Renal Transplantation

1. Can this person receive a kidney: what is the minimal workup that should be done in a healthy kidney transplant candidate?

Luuk Hilbrands, Nijmegen, The Netherlands

2. How long this patient with previous cancer should wait before being wait-listed?

Bruno Watschinger, Vienna, Austria

3. How can I evaluate this extended criteria kidney according to ECD, DCD, KDRI?

Umberto Maggiore, Parma, Italy

4. How should I prevent CMV disease and BK PVN in 2019?

5. How should I personalise maintenance therapy according to donor/recipient factors?

Klemens Budde, Berlin, Germany




1. Volume management throughout the course of AKI: Risk – Oliguria – RRT – Polyuria

Wim Van Biesen, Ghent, Belgium

2. AKI in geriatric population and in frailty

Norbert Lameire, Ghent, Belgium

3. AKI in austere environments

Valerie A. Luyckx, Zürich, Switzerland

4. Biopsy in AKI: WHEN and WHY?: Indicated / non-indicated / contraindicated?

5. Recent clinical trials and update in AKI

Andreas Kribben, Essen, Germany



Peritoneal Dialysis

1. PD catheter insertion and complications

Victoria R. Briggs, Sheffield, United Kingdom

2. How to prescribe APD

Carl M. Öberg, Lund, Sweden

3. Prevention, diagnostics and treatment of peritonitis

Anabela Rodrigues, Porto, Portugal

4. Update on PD solutions

Monika Lichodziejewska-Niemierko, Gdańsk, Poland

5. Changes in peritoneal structure and function with time on PD

Johann Morelle, Brussels, Belgium



Electrolytes and urolithiasis

1. Disorders of sodium and water

Ewout Hoorn, Rotterdam, The Netherlands

2. Hypo- and Hyperkalemia

Felix Knauf, Berlin, Germany

3. Disorders of calcium and magnesium

Pascal Houillier, Paris, France

4. Acid-Base disturbances and stones (case-based)

Nilufar Mohebbi, Zurich, Switzerland

Stephen Walsh, London, United Kingdom

5. Stones and electrolytes (case-based)

Philippe Jaeger, London, United Kingdom



ERA-EDTA Registry

1. Different flavours in RCTs and their analyses

Giovanni Luigi Tripepi, Reggio Calabria, Italy

2. Pros and cons of surrogate outcomes in RCTs

Kitty Jager, Amsterdam, The Netherlands

3. Mendelian randomization to enable causal inference in observational studies

Friedo W. Dekker, Leiden, The Netherlands

4. Directed acyclic graphs (DAGs) to address confounding

Natalie Staplin, Oxford, United Kingdom

5. The health economic toolbox in nephrology






Global and Regional Perspectives





Session 1

Can we talk about regional common fate in Nephrology?

1. The European perspective (epidemiology)

Ziad Massy, Paris, France - ERA-EDTA Registry

2. The role of supranational – regional societies

Goce Spasovski, Skopje, North Macedonia

3. Role of National Registries in Nephrology - Epidemiological and economical point of view

Orsolya Cseprekál, Budapest, Hungary

4. Special issues of AKI and CKD in low- and middle-income countries

Mehmet Sukru Sever, Istanbul, Turkey


Session 2

From the molecule to social determinism. Challenges in Nephrology

1. Translational medicine and real life

Anupan Agarwal, Birmingham, AL, USA

2. Arteriosclerosis in children on dialysis - prevention vs damage limitation

Rukshana Shroff, London, United Kingdom

3. Cardiovascular consequences of paediatric CKD

Dieter Haffner, Hannover, Germany

4. Recent developments in kidney transplantation

Ondrej Viklicky, Prague, Czech Republic

5. Holistic care for psychosocial complications of chronic kidney disease

Ágnes Haris, Budapest, Hungary


Session 3

The roots of adult diseases go back to childhood

1. The role of prematurity in kidney diseases in children and adults

Attila Szabo, Budapest, Hungary

2. Adolescent hypertension: transition from the adolescent to the adult

Kjell Tullus, London, United Kingdom

3. Dialysis: bridging towards transplantation

Lutz Weber, Cologne, Germany

4. Diabetes - the changing face of a disease

Istvan Wittmann, Pecs, Hungary

5. Progression of kidney disease in childhood

Franz Schaefer, Heidelberg, Germany


Session 4

Nephrology: The Hungarian Perspective

1. From Koranyi to WKD - Reestablishment of a European Center

László Rosivall, Budapest, Hungary

2. From RAS to renal tissue repair - visualization of physiology and pathophysiology

Janos Peti-Peterdi, Los Angeles, CA, USA

3. Kidney transplantation from Hepatitis C infected donors to uninfected recipients

Miklos Molnar, Memphis, TN, USA

4. Mysteries of inheritance

Kálmán Tory, Budapest, Hungary